Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis.
about
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolismmiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingHistone Deacetylases and Cardiometabolic DiseasesSirtuins as regulators of metabolism and healthspanMicroRNAs as controlled systems and controllers in non-alcoholic fatty liver diseaseThe role of mammalian sirtuins in the regulation of metabolism, aging, and longevityInterplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogrammingEnergy metabolism in the liverSIRTain regulators of premature senescence and accelerated agingSirtuins in Cancer: a Balancing Act between Genome Stability and MetabolismSirtuins, metabolism, and DNA repairFrom sirtuin biology to human diseases: an updateMicroRNA modulation of cholesterol homeostasisSirtuins in epigenetic regulationThe role of sirtuins in cardiac diseaseSirtuins in metabolism, DNA repair and cancerSIRT6 is required for maintenance of telomere position effect in human cellsSirtuin deacylases: a molecular link between metabolism and immunityFOXO3 growth inhibition of colonic cells is dependent on intraepithelial lipid droplet densityShifting eating to the circadian rest phase misaligns the peripheral clocks with the master SCN clock and leads to a metabolic syndromeNuclear DNA damage signalling to mitochondria in ageingModulation of microRNA Expression in Subjects with Metabolic Syndrome and Decrease of Cholesterol Efflux from Macrophages via microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1 Expression by StatinsSirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activityLiver Patt1 deficiency protects male mice from age-associated but not high-fat diet-induced hepatic steatosisNeural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseMicroRNAs in metabolism and metabolic disordersNAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion.SIRT1 is necessary for proficient telomere elongation and genomic stability of induced pluripotent stem cells.Is SIRT6 Activity Neuroprotective and How Does It Differ from SIRT1 in This Regard?Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism.Sirtuins: guardians of mammalian healthspan.Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient- and exercise-induced stress.Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion.Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancerNAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response.MicroRNAs and lipoproteins: a connection beyond atherosclerosis?Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition.
P2860
Q24305332-F3F11722-F78F-4167-AF42-8AF3BCD44A3AQ24627398-6A688831-F72E-4DA5-913C-858AB064B6CBQ26800062-540EB835-515A-452A-B6CF-8CB3419940A1Q26828939-F9B85FEC-203C-47B1-890F-53357A681588Q26852606-B6CD92BC-120E-41AF-8FF0-99F0BDB50930Q26865526-B856AF8F-7025-4EBC-917F-596949BF2F4AQ26991931-7933E5EA-C4AC-449F-9342-97A8853566CAQ26996783-13EA50F8-7C66-47D3-9589-03BC10F97A50Q26997358-5D49A2A3-36C1-4F91-A8EF-5ECD80E6E621Q27001553-88DEB251-7A78-4930-A38F-65526416976AQ27015759-EC3D6E31-BE2B-4956-9055-8C042359954BQ27022606-B89F75A9-0918-4D9E-B6C5-5DF4E3C955D1Q27026071-75D6EAA4-D1AE-4832-8CD7-590B23D0D0DEQ27026861-1690C378-3F37-465D-BB7A-4E80BAD0DA12Q27693274-F9BB10D1-AD00-4A76-8B83-47D07C46FA34Q28070892-8C875F0E-37C0-4AE7-B030-061F017A2E03Q28114788-741A9C25-3CB8-4A43-9AA1-2ECE2072356FQ28283588-46F89982-DF4A-46C8-B923-DFC371374E24Q28384062-00CB4C5C-6C26-47E4-AE0A-7C48C508D4B6Q28395865-14669B6E-3C9E-4254-BC25-65637A28B202Q28396642-9D09E02E-291A-473C-BD55-340A151327ECQ28551738-3622D7C7-2F1E-4051-87B1-BCBA72AD2BADQ28568033-E4282426-6FC6-4101-B527-C6632671CB04Q28586093-8D571F2F-CCBF-485F-83BF-C504BB4071EDQ30497676-C57D9762-82D7-42D0-9B85-4849B898A5FEQ33607697-217F14FA-D174-4CE0-9F12-64DCE1C33022Q33612997-7A3A3E13-26DA-48EC-A169-11CDA0F29177Q33720228-120510C5-B002-4793-8236-4E148546DD11Q33730161-E5038EC9-E915-476C-90CC-D64B3631CA2FQ33774831-7F1516E2-BA48-42B5-9222-0FB1E7EB48ABQ33803483-CA300B4A-3151-43F7-B04B-3C6711EE7EFEQ33831420-459BCA05-1E3D-446C-8FC9-9F0BBA367162Q33836877-3223F305-4454-4C9A-A078-C7D8BB5A223DQ33860228-31CFBEAD-482C-49FD-9F6F-AF9A2092F935Q33972212-471A3173-D0CD-4A1D-9AC9-32098B26847EQ34061979-228C45AF-26DF-4D99-806E-07315BD68DBBQ34169595-8FB111F3-563A-4A8A-AC32-2E8A5AA259E3Q34281758-E879DF27-51B2-46E1-B8F0-C1A07AFE33FDQ34321706-36B9A810-06EB-45AD-A0A8-6B757A0C12CFQ34341958-D17DF53E-61E1-41A0-B34C-644EF821F23D
P2860
Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@ast
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@en
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@nl
type
label
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@ast
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@en
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@nl
prefLabel
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@ast
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@en
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@nl
P2093
P2860
P1433
P1476
Hepatic-specific disruption of ...... is and triglyceride synthesis.
@en
P2093
Athanassios Vassilopoulos
Chu-Xia Deng
Cuiying Xiao
Guelaguetza Vazquez-Ortiz
Hyun-Seok Kim
Rui-Hong Wang
Sung Hwan Ki
Tyler Lahusen
P2860
P304
P356
10.1016/J.CMET.2010.06.009
P577
2010-09-01T00:00:00Z